Navigation Links
Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
Date:9/8/2010

ST. LOUIS, Sept. 8 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia (VT) ablation.

At the European Cardiology Society Annual Congress in Stockholm last week, the research team led by Dr. Tamas Szili-Torok from the Erasmus Medical Center in Rotterdam presented the first comparative trial in a prospective study of 64 consecutive VT patients, comparing Stereotaxis VT ablation to conventional, non-magnetic ablation.  Acute success was achieved in 97% of the Stereotaxis VT ablation group versus 81% of the manual ablation group.  Patients in the Stereotaxis VT group averaged 50% less x-ray exposure, and after a year, only 14% VT recurrence, versus a 50% recurrence rate among manual ablation patients.  A remarkable 25% reduction in total procedure time was achieved in the Stereotaxis VT group compared to the manual group.

There were no major complications in the Stereotaxis VT group compared to one death in the non-Stereotaxis group, representing a 4% major complication rate.

"The use of Stereotaxis offers major advantages for the ablation of VT," said Dr. Szili-Torok. "We have adopted a 100% utilization rule for our Stereotaxis lab for cardiac arrhythmias due to the significant benefits for our patients as well as for us as operators."

Further, Dr. Arash Arya and colleagues from the University of Leipzig Heart Center in Leipzig, Germany published data from a series of 30 consecutive patients who were suffering from "VT storm," which is three or more VT episodes in a 24 hour period that trigger a shock treatment from an implanted defibrillator device.  While treating VT Storm is extremely challenging, Dr. Arya reported that 70% of the patients
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
2. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
3. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
4. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
5. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
6. Stereotaxis Installs First System in Taiwan
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
10. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
11. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... following is being released by SafeMinds ( www.SafeMinds.org ): ... has publicly denied a vaccine-autism link, while at the ... been awarding damages for vaccine injury to children with ... on verifiable government data, breaks ground in the controversial ...
... Perrigo Company (Nasdaq: PRGO ; TASE) today ... relating to fluticasone lotion brought by Nycomed US Inc. by ... of the settlement, Perrigo can launch a generic version of ... certain circumstances. Cutivate® (fluticasone) lotion is indicated ...
Cached Medicine Technology:83 Cases of Autism Associated with Childhood Vaccine Injury Compensated in Federal Vaccine Court 2Perrigo Announces Settlement of Cutivate Lotion Litigation 2
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2
... , DALLAS, Jan. 11 The American ... effort led by the Department of Health and Human Services ... encourage more Americans to get vaccinated against H1N1. ... people with heart failure or with any cardiovascular disease. Like ...
... researchers suggest , MONDAY, Jan. 11 (HealthDay News) -- A ... genetic variant associated with the aggressiveness of prostate cancer, in ... out cancers that need intensive treatment from those that can ... principle to show that there are variants in the genome ...
... ... , ... Primary care physicians may be able to help increase Americans, willingness to become organ donors ... about end-of-life care, according to a study in the January issue of the Journal of ...
... , , BATESVILLE, Ind., Jan. 11 Hillenbrand, Inc. (NYSE: ... to 1:30 p.m. in New York, N.Y., on Jan. 14, 2010, and ... for Hillenbrand to acquire K-Tron International, Inc. ( KTII). , You are ... hear from and meet members of the Hillenbrand and K-Tron management teams ...
... , FAIRVIEW, Pa., Jan. 11 ... and manufacturer of custom electronic products and systems, today reported results ... , For the fourth quarter of fiscal 2009, the Company ... on sales of $34.1 million, compared to net income of $2.5 ...
... Amounts deemed safe are still too high, researchers say , ... of lead may harm children,s kidneys, say U.S. researchers. , ... per deciliter of blood, according to the U.S. Centers for ... Center study suggests that even levels below 10 micrograms are ...
Cached Medicine News:Health News:American Heart Association Encourages Heart Disease Patients to Get H1N1 Flu Shot in Support of National Influenza Vaccination Week, Jan. 10-16 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 3Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 2Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 3Health News:New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 2Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 3Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 4Health News:Hillenbrand to Host Investor Luncheons in New York City and Boston 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 2Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 3Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 4Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 6Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 7Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 8Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 9Health News:Very Low Levels of Lead Harm Kids' Kidneys: Study 2
ReNu 1 Step Enzymatic Cleaner with ReNu Multi-Purpose Solution removes protein deposits while lenses are being disinfected. Its a one-step process that saves time. Removes stubborn deposits from dai...
...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... intraocular lenses. The instrument consists of a ... implant and divides the implant into two ... halves of the lens so that unwanted ... chamber is avoided. The instrument is passed ...
Medicine Products: